Samsung Biologics agreed to acquire Human Genome Sciences’ Rockville, MD biologics manufacturing site from GSK for $280 million, securing 60,000 liters of cGMP drug-substance capacity and the company's first U.S. production footprint. Samsung said it will retain more than 500 employees and invest to expand and modernize the facility, strengthening U.S. supply-chain resiliency for biologics. The purchase complements Samsung’s existing global capacity and aligns with its Bio Campus expansion plans, signaling continued contract-manufacturing consolidation. For biopharma customers, the deal promises increased North American capacity for clinical and commercial biologics and potential local tech upgrades that could shorten timelines for complex biologic programs.